JP2001509488A - 敗血症治療薬、その製造及び使用 - Google Patents
敗血症治療薬、その製造及び使用Info
- Publication number
- JP2001509488A JP2001509488A JP2000501768A JP2000501768A JP2001509488A JP 2001509488 A JP2001509488 A JP 2001509488A JP 2000501768 A JP2000501768 A JP 2000501768A JP 2000501768 A JP2000501768 A JP 2000501768A JP 2001509488 A JP2001509488 A JP 2001509488A
- Authority
- JP
- Japan
- Prior art keywords
- lbp
- lps
- sepsis
- protein
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000004599 antimicrobial Substances 0.000 title 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims abstract description 37
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims abstract description 35
- 206010040047 Sepsis Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 3
- 239000002158 endotoxin Substances 0.000 claims description 19
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 19
- 241000701447 unidentified baculovirus Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000192125 Firmicutes Species 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 101150072740 Lbp gene Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 claims 2
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 claims 1
- 241001529572 Chaceon affinis Species 0.000 claims 1
- 101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 claims 1
- 101001023407 Mus musculus Lipopolysaccharide-binding protein Proteins 0.000 claims 1
- 101001023403 Rattus norvegicus Lipopolysaccharide-binding protein Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 abstract description 4
- 241001529936 Murinae Species 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000688 bacterial toxin Substances 0.000 description 5
- 231100000699 Bacterial toxin Toxicity 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101710089435 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19729810.9 | 1997-07-11 | ||
| DE19729810A DE19729810C2 (de) | 1997-07-11 | 1997-07-11 | Mittel zur Sepsistherapie, seine Herstellung und seine Verwendung |
| PCT/DE1998/000964 WO1999002178A1 (de) | 1997-07-11 | 1998-04-04 | Mittel zur sepsistherapie, seine herstellung und seine verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001509488A true JP2001509488A (ja) | 2001-07-24 |
| JP2001509488A5 JP2001509488A5 (enExample) | 2005-12-22 |
Family
ID=7835437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000501768A Pending JP2001509488A (ja) | 1997-07-11 | 1998-04-04 | 敗血症治療薬、その製造及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6949512B1 (enExample) |
| EP (1) | EP0999849B1 (enExample) |
| JP (1) | JP2001509488A (enExample) |
| AT (1) | ATE223227T1 (enExample) |
| DE (2) | DE19729810C2 (enExample) |
| DK (1) | DK0999849T3 (enExample) |
| ES (1) | ES2183376T3 (enExample) |
| PT (1) | PT999849E (enExample) |
| WO (1) | WO1999002178A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520422A (ja) * | 2008-04-09 | 2011-07-21 | フォルシュンクスツェントルム ボルステール − ライプニッツエントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 新規抗菌ペプチド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025476A1 (en) * | 1993-04-30 | 1994-11-10 | Incyte Pharmaceuticals, Inc. | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
| EP0664814A1 (en) * | 1993-08-18 | 1995-08-02 | MorphoSys AG | Lipopolysaccharide-binding and neutralizing peptides |
| WO1995008560A1 (en) * | 1993-09-24 | 1995-03-30 | Centocor, Inc. | Novel peptides useful for inhibiting binding of lipopolysaccharides (lps) by lipopolysaccharide binding protein (lbp) |
| US5837810A (en) * | 1994-03-15 | 1998-11-17 | The Scripps Research Institute | Polypeptides of lipopolysaccharide binding protein |
| US5990082A (en) * | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
-
1997
- 1997-07-11 DE DE19729810A patent/DE19729810C2/de not_active Expired - Fee Related
-
1998
- 1998-04-04 PT PT98928139T patent/PT999849E/pt unknown
- 1998-04-04 WO PCT/DE1998/000964 patent/WO1999002178A1/de not_active Ceased
- 1998-04-04 AT AT98928139T patent/ATE223227T1/de not_active IP Right Cessation
- 1998-04-04 DE DE59805440T patent/DE59805440D1/de not_active Expired - Lifetime
- 1998-04-04 ES ES98928139T patent/ES2183376T3/es not_active Expired - Lifetime
- 1998-04-04 DK DK98928139T patent/DK0999849T3/da active
- 1998-04-04 EP EP98928139A patent/EP0999849B1/de not_active Expired - Lifetime
- 1998-04-04 JP JP2000501768A patent/JP2001509488A/ja active Pending
-
2000
- 2000-01-13 US US09/484,121 patent/US6949512B1/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011520422A (ja) * | 2008-04-09 | 2011-07-21 | フォルシュンクスツェントルム ボルステール − ライプニッツエントルム フュール メディツィン ウント ビオヴィッセンシャフテン | 新規抗菌ペプチド |
Also Published As
| Publication number | Publication date |
|---|---|
| DE59805440D1 (de) | 2002-10-10 |
| WO1999002178A1 (de) | 1999-01-21 |
| US6949512B1 (en) | 2005-09-27 |
| DE19729810A1 (de) | 1999-01-14 |
| DK0999849T3 (da) | 2003-01-06 |
| DE19729810C2 (de) | 2000-01-13 |
| EP0999849B1 (de) | 2002-09-04 |
| PT999849E (pt) | 2003-01-31 |
| EP0999849A1 (de) | 2000-05-17 |
| ATE223227T1 (de) | 2002-09-15 |
| ES2183376T3 (es) | 2003-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Engerman et al. | Experimental diabetic retinopathy in dogs | |
| JPH08511682A (ja) | 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用 | |
| US4916117A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
| JP2000509715A (ja) | 炎症を処置するための方法 | |
| Jilma et al. | Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man | |
| US6429188B1 (en) | Method for treating the endotoxic shock in mammals | |
| JP4463885B2 (ja) | 劇症肝炎疾患治療剤 | |
| JP2001509488A (ja) | 敗血症治療薬、その製造及び使用 | |
| JP2694603B2 (ja) | アンギオゲニンの抑制剤 | |
| CN118766933A (zh) | Aldisin化合物在制备治疗炎症性肠病的药物中的应用 | |
| EP0504191B1 (en) | Method and composition for the treatment of mammalian hiv infection | |
| Medici et al. | Effects of drugs on mucus glycoproteins and water in bronchial secretion | |
| Creasey et al. | Pharmacokinetics of aztreonam in elderly male volunteers. | |
| US7306791B2 (en) | Agent for preventing and/or treating multiple organ failure | |
| CN112190708B (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| CN109846863B (zh) | 和厚朴酚的用途 | |
| CN114748609A (zh) | 基于clec18a蛋白的预防和抑制机体炎症反应药物及应用 | |
| JP3961064B2 (ja) | 腎疾患予防及び／又は治療剤 | |
| Samsoon et al. | General anaesthesia and the hypereosinophilic syndrome: severe postoperative complications in two patients | |
| WO1983004260A1 (fr) | Enzyme analogue de la pepsine de leucocyte humain et agent therapeutique contenant cette enzyme en tant qu'ingredient effectif pour le traitement de troubles allergiques, de maladies auto-immunitaires et de tumeurs | |
| AU685413B2 (en) | Method and composition for treatment of patients having decompensated liver disease | |
| US20060067913A1 (en) | HCV therapy | |
| US5750501A (en) | Method and composition for treatment of patients having decompensated liver disease | |
| KR20050034584A (ko) | Ｓｉｒｓ/패혈증의 치료 및 예방 방법 및 이를 위한조성물 | |
| JP4114979B2 (ja) | 拡張型心筋症治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080821 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |